Amsterdam’s ADORE Secures €9M to tackle cancer and neurodegenerative diseases

ADORE to unite thousands of researchers to address major healthcare challenges

Amsterdam's prominence in life sciences and medical research has received a major boost, as the Dutch Research Council (NWO) awarded €9 million to ADORE as part of its Long Term Program. 

The Long Term Program, a 10-year project, will bring together over 2,000 researchers from Cancer Center Amsterdam and Amsterdam Neuroscience to develop personalised treatments by exploring shared disease mechanisms. It aims to improve life expectancy and quality of life as well as address the growing burden of care through collaborations between research institutions, industry, and society.

The investment comes amid projections that cancer cases in the Netherlands will rise from 800,000 in 2022 to 1.4 million by 2031. Meaning 1 in 2 Dutch residents could face a cancer diagnosis in their lifetime. Similarly, dementia rates are expected to affect 1 in 5 people, and multiple sclerosis diagnoses are averaging one per day. To address these challenges, NWO has committed €25 million in total funding across research initiatives.

Collaboration supports Amsterdam’s strong healthcare ecosystem

Amsterdam will host this effort through the ADORE Research & Diagnostics Center, set to become the world's largest onco-neuro campus. The €9 million grant, part of a larger €30 million, 10-year project supported by the ADORE foundation and other partners, adds to Amsterdam’s strong healthcare landscape and will help to address critical health challenges like cancer and dementia through personalised medicine. The city’s efforts are further supported by Amsterdam UMC, which is pushing AI-based research and recently became the first European hospital to complete a double wireless pacemaker operation.

Find out more about the bustling healthcare landscape in Amsterdam